Drug Trial Radar · NCT04411550
Compare Pharmacokinetics, Safety, and Immunogenicity of HLX11 vs. Perjeta in Healthy Chinese Male Subjects
Last checked: Nov 19, 2026Latest source record: May 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
160
Actual
Start
Jul 1, 2020
Primary completion
Jul 1, 2021
Study completion Jul 30, 2021
Sponsor
- Lead sponsor
- Shanghai Henlius BiotechIndustry
- Sponsor type
- Industry
- First posted
- Jun 2, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomised, double-blind, intravenous single-dose, four-arm parallel study designed to compare the PK of HLX11 and US, EU, and CN-sourced Perjeta® in healthy Chinese adult male subjects, and to assess the safety, tolerability, and immunogenicity of these 4 drugs.
Conditions
- Healthy Male Volunteers
Interventions
HLX11Drug
healthy volunteers receive HLX11 (420mg) once
CN-Perjeta(Pertuzumab)Drug
healthy volunteers receive CN-Perjeta (420mg) once
EU-Perjeta(Pertuzumab)Drug
healthy volunteers receive EU-Perjeta (420mg) once
US-Perjeta(Pertuzumab)Drug
healthy volunteers receive US-Perjeta (420mg) once
Primary outcomes
What the sponsor says the trial is designed to measure.
- CmaxTime frame: from predose to 2352 hours (Day 99),13 timepoints
- AUC0~tTime frame: from predose to 2352 hours (Day 99),13 timepoints
- AUC0~infTime frame: from predose to 2352 hours (Day 99),13 timepoints
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second Hospital of Anhui Medical University
Hefei, Anhui, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.